Advantages With Upfront Chemotherapy
00:00:41

Advantages With Upfront Chemotherapy

Bassel El-Rayes, M.D. Professor & Vice Chair For Clinical Research, Department Of Hematology & Medical Oncology Emory University School Of Medicine, John Kauffman Family Professor For Pancreatic Cancer Research Associate Director For Clinical Research, Director Of The Gastrointestinal Oncology Program Winship Cancer Institute Of Emory University Discusses Advantages With Upfront Chemotherapy. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

26 Views
9 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Trending

Advantages With Upfront Chemotherapy
00:00:41

Advantages With Upfront Chemotherapy
26 Views
9 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Financial Toxicity and Equitable Access to Clinical Trials
00:01:22

Financial Toxicity and Equitable Access to Clinical Trials
64 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
CASSINI Study Results: Reduction In Blood Clots When Taking Daily Rivaroxaban, No Increase In Bleeding
00:01:56

CASSINI Study Results: Reduction In Blood Clots When Taking Daily Rivaroxaban, No Increase In Bleeding
77 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
The Role Of BRAF Mutations In Treatment Of Cholangiocarcinoma
00:00:42

The Role Of BRAF Mutations In Treatment Of Cholangiocarcinoma
71 Views
9 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
New Therapies In The Treatment Of Liver Cancer
00:02:54

New Therapies In The Treatment Of Liver Cancer
71 Views
9 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
00:01:57

Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
126 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Discussing REFLECT Phase 3 Study Utilizing Lenvatinib & Recent Approval Of Cabozantinib
00:00:49

Discussing REFLECT Phase 3 Study Utilizing Lenvatinib & Recent Approval Of Cabozantinib
87 Views
9 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
The Role Of I-O In Esophagogastric Cancer Treatment Algorithms
00:02:09

The Role Of I-O In Esophagogastric Cancer Treatment Algorithms
11 Views
9 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Treating Advanced Biliary Cancer: M7824 Data
00:02:09

Treating Advanced Biliary Cancer: M7824 Data
152 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
KEYNOTE-181 Esophageal Cancer Study
00:00:39

KEYNOTE-181 Esophageal Cancer Study
170 Views
9 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Stereotactic Body Radiation Therapy In Early Stage HCC
00:00:34

Stereotactic Body Radiation Therapy In Early Stage HCC
22 Views
9 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Pembrolizumab Monotherapy In Biliary Cancer
00:02:10

Pembrolizumab Monotherapy In Biliary Cancer
94 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Latest Videos

Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians
0:03:47

Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians
4 Views
3 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Intestinal Tumor Commonly Asked Questions
0:03:59

Intestinal Tumor Commonly Asked Questions
4 Views
3 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Drug Resistance Found As Intestinal Tumor
0:11:46

Drug Resistance Found As Intestinal Tumor
13 Views
3 weeks ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer
00:01:16

KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer
174 Views
4 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
00:02:20

When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
217 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
00:02:12

Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
26 Views
5 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login